Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective PlatinumIV Prodrug Against Triple Negative Breast Cancer

Nafees Muhammad; Tan Cai-Ping; Sadia Nasreen; Zong-Wan Mao

doi:10.1002/asia.202100593

Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum^IV Prodrug Against Triple Negative Breast Cancer

Chem Asian J. 2021 Aug 16;16(16):2276-2279. doi: 10.1002/asia.202100593. Epub 2021 Jul 20.

Authors

Nafees Muhammad¹, Tan Cai-Ping¹, Sadia Nasreen², Zong-Wan Mao¹

Affiliations

¹ School of Chemistry, Sun Yat-Sen University, Guangzhou, 510275, P. R. China.
² Department of Environmental Engineering, University of Engineering and Technology (UET), Taxila, Taxila, 47080, Pakistan.

PMID: 34231967
DOI: 10.1002/asia.202100593

Abstract

A mitochondria targeting dual-action platinum^IV prodrug exhibits high anticancer activity in triple negative breast cancer cells. The complex intervenes in several cellular processes including DNA damage, perturbation of mitochondrial bioenergetics and induction of necrosis to kill cancer cells.

Keywords: Doxorubicin; Mitochondria; Necrosis; PlatinumIV; Triple negative breast cancer.

MeSH terms

Antineoplastic Agents / chemistry
Antineoplastic Agents / metabolism
Antineoplastic Agents / therapeutic use
Cell Line, Tumor
Cisplatin / chemistry
Cisplatin / pharmacokinetics*
Cisplatin / pharmacology
DNA, Mitochondrial / drug effects
Doxorubicin / chemistry
Doxorubicin / pharmacokinetics*
Doxorubicin / pharmacology
Humans
Mitochondria / drug effects
Mitochondria / metabolism*
Molecular Structure
Molecular Targeted Therapy
Prodrugs / chemical synthesis
Prodrugs / pharmacokinetics
Prodrugs / pharmacology
Triple Negative Breast Neoplasms / drug therapy*

Substances

Antineoplastic Agents
DNA, Mitochondrial
Prodrugs
Doxorubicin
Cisplatin

Abstract

MeSH terms

Substances

Grants and funding